Results 21 to 30 of about 2,796 (165)
Infection of non-cancer cells: A barrier or support for oncolytic virotherapy?
Molecular Therapy: Oncolytics, 2022 Oncolytic viruses are designed to specifically target cancer cells, sparing normal cells. Although numerous studies demonstrate the ability of oncolytic viruses to infect a wide range of non-tumor cells, the significance of this phenomenon for cancer ...
Victor A. Naumenko +4 more
doaj +1 more source
Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect [PDF]
, 2017 : With the advancement of a growing number of oncolytic viruses (OVs) to clinical development, drug delivery is becoming an important barrier to overcome for optimal therapeutic benefits.
core +1 more source
Molecular Therapy: Oncolytics, 2021 The oncolytic effect of virotherapy derives from the intrinsic capability of the applied virus in selectively infecting and killing tumor cells. Although oncolytic viruses of various constructions have been shown to efficiently infect and kill tumor ...
Divya Ravirala +3 more
doaj +1 more source
Oncolytic virotherapy for ovarian cancer [PDF]
Oncolytic Virotherapy, 2012 In the past two decades, more than 20 viruses with selective tropism for tumor cells have been developed as oncolytic viruses (OVs) for treatments of a variety of malignancies. Of these viruses, eleven have been tested in human ovarian cancer models in preclinical studies.
Li, Shoudong +4 more
openaire +4 more sources
Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances
Molecular Therapy: Oncolytics, 2019 Oncolytic viruses (OVs) are powerful new therapeutic agents in cancer therapy. With the first OV (talimogene laherparepvec [T-vec]) obtaining US Food and Drug Administration approval, interest in OVs has been boosted greatly.
Meijun Zheng +3 more
doaj +1 more source
Oncolytic Virotherapy with Myxoma Virus [PDF]
Journal of Clinical Medicine, 2020 Oncolytic viruses are one of the most promising novel therapeutics for malignant cancers. They selectively infect and kill cancer cells while sparing the normal counterparts, expose cancer- specific antigens and activate the host immune system against both viral and tumor determinants.
Masmudur M. Rahman, Grant McFadden
openaire +2 more sources
Oncolytic Virotherapy in Glioma Tumors [PDF]
International Journal of Molecular Sciences, 2020 Glioma tumors are one of the most devastating cancer types. Glioblastoma is the most advanced stage with the worst prognosis. Current therapies are still unable to provide an effective cure. Recent advances in oncolytic immunotherapy have generated great expectations in the cancer therapy field. The use of oncolytic viruses (OVs) in cancer treatment is
Sergio Rius-Rocabert +4 more
openaire +3 more sources
Targeting tumor vasculature through oncolytic virotherapy: recent advances [PDF]
, 2015 The oncolytic virotherapy field has made significant advances in the last decade, with a rapidly increasing number of early- and late-stage clinical trials, some of them showing safety and promising therapeutic efficacy.
Merchan, Jaime R +1 more
core +1 more source
Implications of immune cells in oncolytic herpes simplex virotherapy for glioma [PDF]
, 2022 Despite current progress in treatment, glioblastoma (GBM) remains a lethal primary malignant tumor of the central nervous system. Although immunotherapy has recently achieved remarkable survival effectiveness in multiple malignancies, none of the immune ...
Yoo, Ji Young +5 more
core +4 more sources
A progressive stage IIIB melanoma treated with oncolytic ECHO-7 virus: A case report
SAGE Open Medical Case Reports, 2020 Melanoma is an aggressive skin cancer form with a grave prognosis. Current results suggest that oncolytic virus treatment of melanoma has a high therapeutic potential. ECHO-7 (Rigvir) is the first oncolytic virus registered in Latvia.
Vladimirs Sorokins +6 more
doaj +1 more source